Navigation Links
Tapestry Pharmaceuticals to Present Data on TPI 287 at the 2007,AACR Annual Meeting

BOULDER, Colo., March 14, 2007 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. today announced that it will present new data at the 2007 American Association for Cancer Research (AACR) Annual Meeting, April 14-18 in Los Angeles, Calif. Scientists from Tapestry Pharmaceuticals will discuss preclinical data on the Company's lead compound, TPI 287, in a poster presentation entitled, "TPI 287 crosses the blood brain barrier and contributes to antitumor activity in the U251 glioblastoma intracranial tumor model in nude mice." The poster (#1441) will be presented Sunday, April 15, 2007 from 1:00 - 5:00 p.m. at the Experimental and Molecular Therapeutics 8 session.

About TPI 287

TPI 287, a proprietary next generation taxane, is Tapestry's lead clinical compound. This compound was designed to overcome multi-drug resistance in solid tumors that have become resistant to taxane therapy. In preclinical testing, TPI 287 demonstrated the ability to inhibit tumor cell growth in a number of in vitro cell lines and in general, has shown equivalent inhibition of tumors in certain animal xenograft models when tested against standard comparative agents. In some cell lines resistant to taxanes, TPI 287 has demonstrated greater inhibition of tumors in certain animal xenograft models when tested against standard comparative agents. The in vitro activity was seen across multiple cell lines including cell lines known to be sensitive to taxanes and cell lines known to be resistant to taxanes. Taxane sensitive cell lines in which TPI 287 has shown activity include cell lines derived from breast cancer, uterine cancer and non-small cell lung cancer. Taxane resistant cell lines in which TPI 287 shows greater activity include lines derived from breast and colon cancer. In in vivo testing TPI 287 demonstrated greater tumor growth inhibition activity in tumor cell lines with multiple drug resistance, MDR1.

TPI 28
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Tapestry Pharmaceuticals Present Data TPI the AACR Annual Meeting
(Date:5/15/2008)...N.J., May 15 /- Schering-Pl...ing the science and treatment of,chronic hepatitis...a from,several clinical studies with PEGINTRON(TM)..., USP) combination therapy, as well as boceprevir,...nhibitor, will be presented at,the 39th annual Dig...
(Date:5/15/2008)...ults obtained with a newly cleared device to ident...nterest that are associated with ...Mass., May 15 /- InfraReDx, Inc. toda...n Royal Oak, Mich., have,successfully used its Lip...ergoing a cardiac catheterization. This is the fir...
(Date:5/15/2008)...15 /- CenterWatch, a publishing and,i...arch about clinical,trials, finds that investigati...ronic data capture) systems. More than 75% of resp...hat they had been trained on three or more,EDC sys...ffectiveness of,their EDC training had improved., ...
(Date:5/15/2008)...ortunity Remains for an Antiplatelet Therapy that,... the Combination of Plavix/Iscover and Aspirin...s, WALTHAM, Mass., May 15 /- Decisio...nd advisory firms for pharmaceutical and,healthcar...fient offers,improvement in patient compared to Sa...
Breaking Medicine Technology:Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 7First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 2First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 3First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 4CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3Brain patterns of former anorexics reveal clues to disorders lasting impact 7345 1Brain patterns of former anorexics reveal clues to disorders lasting impact 7345 2Brain patterns of former anorexics reveal clues to disorders lasting impact 7345 3DNA methylation shown to promote development of colon tumors 1407 1DNA methylation shown to promote development of colon tumors 1407 2DNA methylation shown to promote development of colon tumors 1407 3Thoratec Announces Unanimous FDA Advisory Panel Recommendation for Approval of HeartMate II 28R 29 for Bridge to Transplantation 7343 1Thoratec Announces Unanimous FDA Advisory Panel Recommendation for Approval of HeartMate II 28R 29 for Bridge to Transplantation 7343 2Thoratec Announces Unanimous FDA Advisory Panel Recommendation for Approval of HeartMate II 28R 29 for Bridge to Transplantation 7343 3On World AIDS Day CHF International Calls for Community Mobilization and Local Capacity Building to Fight HIV AIDS 956 1On World AIDS Day CHF International Calls for Community Mobilization and Local Capacity Building to Fight HIV AIDS 956 2On World AIDS Day CHF International Calls for Community Mobilization and Local Capacity Building to Fight HIV AIDS 956 3
...pr 25, 2007 - XenoPort, Inc.,(Nasdaq: XNPT) today ... trial of XP13512 for the treatment of symptoms of...onstrated statistically,significant improvements c...ints of the trial and was well tolerated., "These ...,advance for XenoPort, its partners and, potential...
...pr 25, 2007 - DuoCort AB,today announced that resu...l release hydrocortisone tablets for adrenal insuf...gress of Endocrinology on,April 30 in Budapest. Th...of the new hydrocortisone tablets in healthy,volun...Cort 5 mg and 20 mg,hydrocortisone dual-release ta...
Other Medicine Technology:XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512,in Restless Legs Syndrome 2XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512,in Restless Legs Syndrome 3XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512,in Restless Legs Syndrome 4XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512,in Restless Legs Syndrome 5DuoCort AB: DuoCort announces Phase I Data Presentation at the,European Congress of Endocrinology 2
(Date:5/16/2008)...rs More than 500 Workers, WASHINGTON, May 16 /PRN...d emergency medical technicians in the Greater Por...ratified their first-ever contract as,Teamsters., ... now covered by a,strong contract that gives them ...id Teamsters General President Jim Hoffa., The wo...
(Date:5/16/2008)...ic disease sufferers gain benefit from calcitriol,...Day News) -- Taking activated vitamin D may cut th... chronic kidney disease by about one quarter, a ne... more than 1,400 patients, those being treated wit... had their overall risk of death lowered by 26 per...
(Date:5/16/2008)...la., May 16 /PRNewswire-USNewswire/- "Huh, what di...mericans, particularly our,children. More than 30 ...e,significant hearing loss and the numbers are gro... school age children have some form of hearing,los...l and economic problem,is what led Kathlyn Maguire...
(Date:5/16/2008)...ast Scheduled for May 19 at 10:15 a.m. Eastern Tim...ponse Biomedical,Corporation (TSX: RBM, OTCBB: RPB...tive Officer, is scheduled to present at the Rodma...e on Monday May 19th at 10:15 a.m.,EDT., A live w...he Company,s,Web site at, http://www.responsebio.c...
Breaking Medicine News(10 mins):Health News:Vitamin D Use Linked to Lower Mortality in Kidney Patients 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 3Health News:Response Biomedical Corporation to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference 2
...lder women with depression may have an increased r...New York studied more than 93,600 older women who ...rvational Study (WHI-OS). The WHI-OS is a long-ter...d lifestyle factors influence the risk of heart di...
...cers cause 16,000 deaths each year due to the spre...Previously, the best way to predict whether melano...ness. It was believed the thicker a tumor was, the... many thin melanomas spread and only 40 percent of...
...t study by Taiwanese experts , people buying the p...tually none. St John's Wort, or Hypericum, can ha...arn it can interfere with the effects of other med...d had as much of the active ingredient as claimed,...
... occurs without warning when a woman develops dang...out 5 percent of pregnant women are affected by th...n their urine. If the condition progresses to ecla...result.While doctors can treat the seizures and hi...
Other Medicine News:Health News:Predicting The Risk Of Preeclampsia During Pregnancy 2
The Quinton Q-Stress Cardiac Stress Monitor combines Quinton algorithms, unique baseline wander and muscle artifact filters, and 8000 samples per second to provide the highest ECG fidelity in the ind
...gh in non-invasive cardiac diagnosis, the fully fe...only stress test system that measures T-wave alter...ck provides a quality control facility, this combi...filters the signal ensuring outstanding and noise-...
...90E Automatic Chart Projector makes refracting eas...ts you program up to 33 charts in any order you wi...kened room simply by pressing one button each time...the CP-690E's programmable random access gives you...
The Urchin heart positioner provides excellent access to target coronaries while minimizing hemodynamic instability
Medicine Products: